Structure and Function of Platelet Glycoprotein Ib-IX-V Complex
血小板糖蛋白 Ib-IX-V 复合物的结构和功能
基本信息
- 批准号:8207976
- 负责人:
- 金额:$ 35.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-02-01 至 2014-12-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdhesionsArterial InjuryBindingBinding SitesBiochemicalBloodBlood PlateletsBlood VesselsCalculiCardiovascular DiseasesCell membraneChimera organismCoagulation ProcessComplexCovalent InteractionCrystallographyDiseaseDisease susceptibilityDissectionEngineeringFundingFutureGlycoprotein IbHematological DiseaseHemorrhageHemostatic AgentsHemostatic functionHumanHuman Cell LineIn VitroIndividualInjuryIntegral Membrane ProteinLeadLearningLengthLigand BindingLigandsLigationLinkMammalian CellMediatingMembraneMembrane GlycoproteinsMolecularMutagenesisMutationNMR SpectroscopyPathologyPeptidesPhysiological ProcessesPhysiologyPlatelet ActivationPlatelet GlycoproteinsProcessProteinsPublic HealthReagentRecombinantsRegulationResolutionRoleSignal TransductionSiteStructureTertiary Protein StructureTestingThrombinTransmembrane DomainVariantWorkX-Ray Crystallographybasecrosslinkdisease-causing mutationimprovedinsightinterestinterfacialnanodisknovel therapeuticsoligomycin sensitivity-conferring proteinprotein complexpublic health relevancereceptorreconstitutionresponsestoichiometrytoolvon Willebrand Factor
项目摘要
DESCRIPTION (provided by applicant): As the second most expressed membrane receptor complex on the platelet surface, the glycoprotein (GP) Ib-IX-V complex is essential to platelet physiology. It is identified primarily as the receptor for a number of hemostatically important proteins including von Willebrand factor and thrombin. It has also been implicated in the genesis and clearance of platelets. Malfunction of this multi-subunit receptor complex can lead to severe bleeding diathesis and contribute to many cardiovascular diseases. However, how this complex carries out its multi-faceted functions is not clear, primarily due to the lack of understanding of its structure and organization. The GPIb-IX-V complex comprises of 4 different type I transmembrane proteins, with the GPIb-IX complex possessing the ligand-binding activity and signaling capability. We hypothesize that inter-subunit interactions are important to the functions and regulation of the GPIb-IX complex. In this project, we aim to elucidate its organizing principle and to explore functional roles of inter-subunit interactions. In Specific Aim 1, to characterize the postulated weak interaction between the ectodomains of GPIb1 and GPIX subunits, we will define the interfacial region and residues in both domains and determine their roles in the assembly and inside-out regulation of the receptor complex. Specific Aim 2 is to elucidate the structural basis for the inter-ectodomain interactions. Structure of the recombinant GPIb2 ectodomain will be determined by X-ray crystallography. Engineered GPIX variants with improved stability that retain the native binding region to GPIb2 and GPIb1 will be produced for structural determination and functional analysis. Specific Aim 3 is to elucidate the structural basis for the interaction among transmembrane helices in the GPIb-IX complex by heteronuclear triple resonance NMR spectroscopy. Overall, careful biochemical and structural dissection of individual interactions in isolated protein domains, in transfected mammalian cells and in human platelets will help to elucidate the likely structural changes in the GPIb-IX complex in response to intracellular regulatory signals and ligand binding, and to provide insights on the molecular basis for GPIb-IX-related diseases. This project will also afford us the opportunity to develop tools and reagents to specifically perturb the inter-subunit interaction of interest, which may lead to novel therapeutic strategies.
PUBLIC HEALTH RELEVANCE:
The glycoprotein Ib-IX-V complex in the platelet helps the blood to clot properly. Malfunction of this complex leads to severe bleeding and can contribute to many cardiovascular diseases. This project seeks to determine the structure of this complex and to learn how it functions and how it is regulated.
描述(由申请方提供):作为血小板表面上表达第二多的膜受体复合物,糖蛋白(GP)Ib-IX-V复合物对血小板生理学至关重要。它主要被鉴定为许多止血重要蛋白质的受体,包括血管性血友病因子和凝血酶。它也与血小板的生成和清除有关。这种多亚基受体复合物的功能障碍可导致严重的出血素质,并有助于许多心血管疾病。然而,这个综合体如何履行其多方面的职能尚不清楚,主要是由于对其结构和组织缺乏了解。GPIb-IX-V复合物由4种不同的I型跨膜蛋白组成,其中GPIb-IX复合物具有配体结合活性和信号传导能力。我们假设亚基间的相互作用对GPIb-IX复合物的功能和调节很重要。在这个项目中,我们的目标是阐明其组织原理,并探讨亚基间相互作用的功能作用。在具体目标1中,为了表征GPIb 1和GPIX亚基的胞外域之间假定的弱相互作用,我们将定义两个域中的界面区域和残基,并确定它们在受体复合物的组装和由内而外调节中的作用。具体目标2是阐明胞外域间相互作用的结构基础。重组GPIb 2胞外域的结构将通过X射线晶体学确定。将产生具有改进的稳定性的工程化GPIX变体,其保留GPIb 2和GPIb 1的天然结合区,用于结构测定和功能分析。具体目标3是阐明的结构基础之间的相互作用的跨膜螺旋GPIb-IX复合物的异三重共振NMR光谱。总体而言,在分离的蛋白质结构域中,在转染的哺乳动物细胞和人血小板中的个体相互作用的仔细的生物化学和结构解剖将有助于阐明GPIb-IX复合物响应于细胞内调节信号和配体结合的可能的结构变化,并提供GPIb-IX相关疾病的分子基础上的见解。该项目还将为我们提供开发工具和试剂的机会,以专门干扰感兴趣的亚基间相互作用,这可能会导致新的治疗策略。
公共卫生相关性:
血小板中的糖蛋白Ib-IX-V复合物有助于血液正确凝结。这种复合物的功能障碍会导致严重出血,并可能导致许多心血管疾病。该项目旨在确定这一综合体的结构,并了解它如何运作以及如何受到监管。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Renhao Li其他文献
Renhao Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Renhao Li', 18)}}的其他基金
GPIb-IX and VWF in thrombosis and thrombocytopenia
GPIb-IX 和 VWF 在血栓形成和血小板减少症中的作用
- 批准号:
10574144 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Conformational activation of von Willebrand factor
血管性血友病因子的构象激活
- 批准号:
9754253 - 财政年份:2018
- 资助金额:
$ 35.96万 - 项目类别:
Conformational activation of von Willebrand factor
血管性血友病因子的构象激活
- 批准号:
10183306 - 财政年份:2018
- 资助金额:
$ 35.96万 - 项目类别:
Conformational activation of von Willebrand factor
血管性血友病因子的构象激活
- 批准号:
9982098 - 财政年份:2018
- 资助金额:
$ 35.96万 - 项目类别:
Specific Inhibition of Ectodomain Shedding of GPIb-alpha
特异性抑制 GPIb-α 的胞外域脱落
- 批准号:
8212483 - 财政年份:2011
- 资助金额:
$ 35.96万 - 项目类别:
Specific Inhibition of Ectodomain Shedding of GPIb-alpha
特异性抑制 GPIb-α 的胞外域脱落
- 批准号:
8047809 - 财政年份:2011
- 资助金额:
$ 35.96万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 35.96万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 35.96万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 35.96万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 35.96万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 35.96万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 35.96万 - 项目类别: